← Phathom Pharmaceuticals, Inc.
| Annual Trend | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0 | $1.1m |
$1.1m
+0.18%
|
$41k
-96.24%
|
$0
-100.00%
|
$682k |
$55.3m
+8001.47%
|
$175.1m
+216.93%
|
$239.7m
+36.86%
|
|
| Cost of revenue | $20k |
$100.4m
+501700.00%
|
$99.2m
-1.12%
|
$72.4m
-27.07%
|
$0
-100.00%
|
$167k |
$8.0m
+4674.25%
|
$22.6m
+183.44%
|
$40.9m
+81.11%
|
|
| Cost of Goods and Services Sold | — | — | — | — | — | $167k |
$8.0m
+4674.25%
|
$22.6m
+183.44%
|
$40.9m
+81.11%
|
|
| Gross Profit (derived) | ($20k) |
($99.3m)
-496255.00%
|
($98.1m)
+1.13%
|
($72.3m)
+26.30%
|
$0
+100.00%
|
$515k |
$47.3m
+9080.39%
|
$152.5m
+222.58%
|
$198.7m
+30.31%
|
|
| Research and development | $20k | $20.4m | $98.1m | $72.3m | $71.4m | $49.9m | $34.1m | $32.8m | $30.1m | |
| Selling, general and administrative | $1.2m | $6.9m | $27.5m | $62.7m | $101.0m | $117.9m | $290.7m | $279.7m | $209.3m | |
| Marketing and Advertising Expense | — | — | — | — | — | — | $61.3m | $61.3m | — | |
| Operating Lease, Expense | — | — | $500k | $700k | $1.0m | $1.1m | $1.1m | $1.0m | — | |
| Restructuring and Related Cost, Incurred Cost | — | — | — | — | — | — | — | $9.2m | — | |
| Total operating expenses | $1.2m | $106.2m | $125.7m | $135.1m | $172.4m | $167.8m | $324.7m | $312.5m | $280.3m | |
| Loss from operations | ($1.2m) |
($106.2m)
-8570.61%
|
($125.7m)
-18.31%
|
($135.1m)
-7.49%
|
($172.4m)
-27.66%
|
($167.3m)
+2.97%
|
($277.5m)
-65.84%
|
($160.0m)
+42.34%
|
— | |
| Operating Income (Loss) | ($1.2m) |
($106.2m)
-8570.61%
|
($125.7m)
-18.31%
|
($135.1m)
-7.49%
|
($172.4m)
-27.66%
|
($167.3m)
+2.97%
|
($277.5m)
-65.84%
|
($160.0m)
+42.34%
|
($40.6m)
+74.60%
|
|
| Interest expense | $13k | $4.2m | ($4.6m) | ($6.8m) | ($27.3m) | ($42.0m) | ($72.0m) | ($68.1m) | $63.4m | |
| Interest income | — | $1.1m | $1.1m | $41k | $2.1m | $7.9m | $15.2m | $7.0m | $5.9m | |
| Other expense, net | — | ($10k) | ($8k) | ($2.1m) | ($110k) | ($188k) | ($8k) | ($190k) | — | |
| Other Nonoperating Income (Expense) | — | ($10k) | ($8k) | ($2.1m) | ($110k) | ($188k) | ($8k) | ($190k) | — | |
| Other Expenses | — | — | $322k | — | — | — | — | — | — | |
| Total other expense | ($63k) | ($148.9m) | ($3.4m) | ($8.8m) | ($25.3m) | ($34.3m) | ($56.9m) | ($61.3m) | — | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | — | — | — | — | — | — | — | ($221.2m) | ($99.1m) | |
| Income Tax Expense (Benefit) | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | |
| Net loss and comprehensive loss | ($1.3m) | ($255.1m) | ($129.1m) | ($143.9m) | ($197.7m) | ($201.6m) | ($334.3m) | ($221.2m) | — | |
| Net loss per share, basic | ($0) | ($22) | ($4) | ($4) | ($5) | ($4) | ($5) | ($3) | — | |
| Net loss per share, diluted | ($0) | ($22) | ($4) | ($4) | ($5) | ($4) | ($5) | ($3) | — | |
| Net Income (Loss) Attributable to Parent | ($1.3m) |
($255.1m)
-19708.31%
|
($129.1m)
+49.41%
|
($143.9m)
-11.48%
|
($197.7m)
-37.42%
|
($201.6m)
-1.96%
|
($334.3m)
-65.84%
|
($221.2m)
+33.82%
|
($99.1m)
+55.22%
|
|
| Earnings Per Share, Basic | ($0) | ($22) | ($4) | ($3.89) | ($5.05) | ($3.93) | ($5.29) | ($3.03) | ($1.25) | |
| Earnings Per Share, Diluted | ($0.21) | ($22.45) | ($3.88) | ($3.89) | ($5.05) | ($3.93) | ($5.29) | ($3.03) | ($1.25) | |
| Weighted-average shares of common stock outstanding, basic | — | — | — | 37.0m | 39.1m | 51.3m | 63.2m | 72.9m | 78.3m | |
| Weighted-average shares of common stock outstanding, diluted | — | — | — | 37.0m | 39.1m | 51.3m | 63.2m | 72.9m | 78.3m | |
| Weighted Average Number of Shares Outstanding, Basic | — | — | — | 37.0m | 39.1m | 51.3m | 63.2m | 72.9m | 78.3m | |
| Weighted Average Number of Shares Outstanding, Diluted | — | — | — | 37.0m | 39.1m | 51.3m | 63.2m | 72.9m | 78.3m |